First Human Study: Novel Immune Modulator RO7497987 Shows Safety and Boosts Dendritic Cells
Background
FLT3L (Fms-like tyrosine kinase 3 ligand) is a critical cytokine that promotes the growth and differentiation of hematopoietic stem cells and progenitor cells, particularly dendritic cells (DCs), which are specialized immune cells essential for initiating robust adaptive immune responses against cancer and infectious diseases. While boosting DC function is a promising strategy in immunotherapy, there remains a need for novel, well-tolerated agents that can effectively expand DC populations in vivo. This Phase Ia study aimed to evaluate the safety, tolerability, pharmacokinetics, and preliminary pharmacodynamic effects of RO7497987, a novel FLT3L-fragment Fc fusion protein, in healthy adult volunteers.
Results
RO7497987 demonstrated a favorable safety profile across all dose levels, with no dose-limiting toxicities or serious adverse events reported among the 64 subjects. The most frequently observed adverse events were mild and transient, primarily injection site reactions, occurring in 15.6% of treated subjects compared to 4.7% in the placebo group. Pharmacokinetic analysis revealed a dose-proportional increase in systemic exposure (AUC and Cmax) and a terminal half-life ranging from 7 to 10 days, supporting a convenient weekly or bi-weekly dosing schedule. > Treatment with RO7497987 resulted in a significant and dose-dependent expansion of circulating dendritic cell (DC) populations, with the highest MAD dose (0.5 mg/kg weekly) leading to a 2.5-fold increase in total DCs compared to placebo (p<0.001). Specifically, conventional DC subsets, cDC1 and cDC2, showed robust increases of 180% and 150% respectively, peaking around 7 days post-dose and remaining significantly elevated for up to 4 weeks.
Why It Matters
This landmark Phase Ia study provides compelling evidence that RO7497987 is safe, well-tolerated, and highly effective at expanding dendritic cell populations in healthy humans, a crucial step for boosting innate and adaptive immunity. The observed robust and sustained increase in circulating DCs suggests its significant potential to enhance the efficacy of existing cancer immunotherapies, improve vaccine responses, or serve as a standalone treatment for immunodeficiency states. These positive safety and pharmacodynamic results strongly support the continued clinical development of RO7497987 as a novel immunomodulatory agent. Future efforts will focus on Phase II trials to evaluate its therapeutic utility in specific patient populations, such as those with advanced malignancies or chronic infections.